Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.14309/ajg.0000000000003108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oligometastatic Esophagogastric Cancer: Does It Exist and How Do We Treat It?
Curr Oncol Rep
January 2025
Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Purpose Of The Review: This narrative review aims to provide an overview of recently completed randomized trials and expert consensus recommendations, and their implications for clinical practice and future trial design in patients with de-novo esophagogastric oligometastatic disease (OMD).
Recent Findings: The IKF-575/RENAISSANCE phase III trial showed no significant overall survival difference between systemic therapy alone and systemic therapy combined with local therapy for patients with gastric or gastroesophageal junction cancer and de-novo OMD, except for patients with retroperitoneal lymph node metastases only. The ESO-Shanghai 13 phase II trial demonstrated superiority of adding local therapy to systemic therapy for progression-free and overall survival in oligometastatic esophageal squamous cell carcinoma.
Natural History of Symptoms in Patients With Esophagogastric Junction Outflow Obstruction Using Standardized Surveys.
Cureus
November 2024
Department of Medicine, Division of Gastroenterology and Hepatology, Penn State College of Medicine, Hershey, USA.
Background Our aim was to assess the clinical presentation and outcomes of patients with a manometric diagnosis of esophagogastric junction outflow obstruction (EGJOO) using standardized symptom surveys and comparison to a cohort who were referred for manometry but who had a normal study. Methods We followed a cohort of adult patients without a mechanical obstruction who underwent high-resolution manometry at our medical center from 9/12/19 to 10/4/21 for 16 months. Results Thirty-seven patients with EGJOO (age: 60.
View Article and Find Full Text PDFPrevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS.
Gastric Cancer
December 2024
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Background: Microsatellite instability (MSI)-high tumors represent a distinct, small-fraction subtype in esophagogastric junction cancer or gastric cancer (GC), yet their clinical significance remains poorly understood. This study aimed to investigate the prevalence and clinicopathological features of chemotherapy-naïve metastatic or recurrent MSI-high GC as a prescreening study for a phase II trial of nivolumab plus ipilimumab.
Methods: Key inclusion criteria included metastatic or recurrent adenocarcinoma of GC, ECOG performance status of 0 or 1, and no prior systemic therapy for metastatic or recurrent disease.
Look above the IRP: predicting abnormal confirmatory testing in patients with esophagogastric junction outflow obstruction.
Therap Adv Gastroenterol
December 2024
Division of Gastroenterology & Hepatology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Perelman Center for Advanced Medicine, 750 South 3400 Civic Center Blvd, Philadelphia, PA 19104, USA.
Background: Esophagogastric junction outflow obstruction (EGJOO) is a manometric diagnosis based on Chicago Classification version 4.0 (CC4.0) that requires confirmatory testing for clinical relevancy.
View Article and Find Full Text PDFCanadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma.
Curr Oncol
December 2024
Unity Health Toronto, University of Toronto, Toronto, ON M5B 1W8, Canada.
Gastric cancer is common globally and has a generally poor prognosis with a low 5-year survival rate. Targeted therapies and immunotherapies have improved the treatment landscape, providing more options for efficacious treatment. The use of these therapies requires predictive biomarker testing to identify patients who can benefit from their use.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!